Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Filed with TSE · · 2 pages · English
Watch Chugai Pharmaceutical's latest callChugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call · Replay · Jul 24Read the transcript of Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings CallChugai Pharmaceutical Co., Ltd. on 6ix
Story so far
- Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
- Chugai Pharmaceutical - Notice Regarding Discontinuation of Development of GYM329 in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy
- Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)
Earlier from Chugai Pharmaceutical
- Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
- Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
- Chugai Announces 2026 2nd Quarter Results
- CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
- F. Hoffmann-La Roche Announces Half Year Results 2026
Later from Chugai Pharmaceutical
- F. Hoffmann-La Roche Announces Third Quarter Sales 2026
- CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
- Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Follow Chugai Pharmaceutical into a list and get an email when it puts out news.
Follow Chugai Pharmaceutical